The first clinically validated algorithm to access HER2 expression in pathologic specimens was developed in breast cancer, utilizing a combination of immunohistochemistry (IHC) and in situ hybridization when IHC results were unclear [38]. Here, ERBB2 is linked to breast carcinoma.